Well, a lot of the patients are seeing a benefit. Also, if they end phase 1 there will be a gap of time between phase 1 and phase 2 ovarian where no one gets any Kevetrin. Furthermore, anyone outside of Ovarian patients will have no access to Kevetrin once phase 1 ends...so from the humanitarian perspective extending it is a good thing. Remember, most of these patients are on death's door. Phase 1 Kevetrin gives them a chance at indefinite stabilization or improvement without severe side effects.
From the scientific perspective you can be sure that the Dr. Shapiro knows these aren't optimized. This isn't some slouch team so obviously they want to see more results for a reason. Whether that's good or bad for us I don't know.
News 
Market Data 
Discover 
